CN105833025A - Drug for treating gout - Google Patents
Drug for treating gout Download PDFInfo
- Publication number
- CN105833025A CN105833025A CN201610287701.7A CN201610287701A CN105833025A CN 105833025 A CN105833025 A CN 105833025A CN 201610287701 A CN201610287701 A CN 201610287701A CN 105833025 A CN105833025 A CN 105833025A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- roots
- gout
- chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a drug for treating gout .The drug for treating gout is prepared from, by weight, 4 parts of pseudobulb of appendiculate cremastra, 10 parts of chingma abutilon seeds, 12 parts of roots-barks of Chinese hydrangeavine, 22 parts of common lantana roots, 7 parts of roots of Chinese trumpetcreeper, 30 parts of ficus sarmentosa var .henryi, 1 parts of Chinese asafetida, 12 parts of sevenlobed yam rhizomes and 10 parts of glossy privet fruits .During application, the pseudobulb of appendiculate cremastra clears away heat and toxic materials, reduces swelling and removes stasis; the chingma abutilon seeds relieve stranguria by diuresis, lubricate the intestines, relax the bowels and promote lactation; the roots-barks of Chinese hydrangeavine relax tendons, activate collaterals, dispel the wind-evil and invigorate the circulation of blood; the common lantana roots clear away heat-fire, relieve internal heat or fever and remove stasis; the roots of Chinese trumpetcreeper cool blood, dispel the wind-evil, activate blood and dredge collaterals; the ficus sarmentosa var .henryi dispels wind, eliminates dampness, relieves swelling and pain, relieves internal heat or fever and kills parasites; the Chinese asafetida eliminates symptoms, removes qi stagnation, kills parasites and stops malaria; the sevenlobed yam rhizomes expel wind-damp and eliminate damp turbidity; the glossy privet fruits nourish the liver and kidney, clear away deficient heat and improve eyesight .The medicinal materials are applied in combined mode to play the effects of dispelling the wind-evil, resolving dampness, promoting menstruation, removing stasis, tonifying the spleen and kidney, cooling blood and dredging collaterals .Clinical experiments prove that the drug can safely and effectively treat the gout.
Description
Technical field
The present invention relates to a kind of Chinese medicine, be specifically related to a kind of medicine for treating gout.
Background technology
Gout is one group and looks sidelong at cry of certain animals disease caused by metabolism disorder, with hyperuricemia and the gouty acute arthritis recurrent exerbation, tophaceous deposition, tophaceous chronic arthritis and the joint deformity that cause therefrom, and often involve kidney and cause chronic interstitial nephritis and uric acid kidney stones to be formed as Major Clinical feature.Being divided into constitutional and the big class of Secondary cases two according to the cause of disease, constitutional person's cause of disease, in addition to minority causes due to enzyme defect, does not illustrates mostly, often accompanies hyperlipemia, obesity, diabetes, hypertension, arteriosclerosis and coronary heart disease etc., belongs to hereditary.Secondary cases person can be caused by many reasons such as nephropathy, hematopathy and medicines.Primary disease is more common in more than 40 years old male, and the women after menopause also has a survivor.Primary disease is often forfeited one's integrity due to food and drink, overwork, is caught cold or the recurrence of the many factors such as infection, more with spring and autumn outbreak, and often in sudden onset at midnight.Primary disease, in addition to medicine causer, mostly lacks etiological treatment, thus can not effect a radical cure, and late period often accompanies renal insufficiency.
Gout belongs to the categories such as " arthromyodynia ", " severe and migratory arthralgia ", " lumbago " of the traditional Chinese medical science.
Classification
Gout can be divided into constitutional and the big class of Secondary cases two according to cause of disease difference.Primary gout refers on the basis of getting rid of other diseases, caused by congenital purine metabolic disturbance and (or) uric acid excretion disorder；Secondary gout refers to be secondary to uricopoiesis caused by underexcretion caused by kidney disease or some drugs, myeloproliferative disease and chemotherapy of tumors and increases.
The cause of disease
The most important biochemical basis of gout is hyperuricemia.Adult normal about produces uric acid 750mg every day, wherein 80% is endogenous, 20% is exogenous uric acid, these uric acid enter uric acid metabolism pond (about 1200mg), uric acid about 60% in every day metabolic pool carries out metabolism, and wherein 1/3 about 200mg is through intestinal catabolism, and 2/3 about 400mg is through renal excretion, thus stablizing of internal uric acid level can be maintained, any of which link goes wrong and all may result in hyperuricemia.
1. primary gout
There is heritability more, but clinic has gout family history person only to account for 10%～20%.Uricopoiesis too much accounts for 10% in the cause of disease of primary hyperuricemia.Its reason is mainly purine metabolism enzyme defect, and hypoxanthine guanine phosphoribosyltransferase (HGPRT) lacks and phosphoribosylpyrophosphate salt (PRPP) synthase activity is hyperfunction.Primary renal underexcretion accounts for the 90% of primary hyperuricemia, and concrete pathogenesis is unclear, for polygenic inheritance disease, but may should get rid of kidney organic disease.
2. secondary gout
Finger is secondary to a kind of clinical manifestation during other diseases, it is possible to caused by some drugs.Myeloproliferative disease such as leukemia, lymphoma, multiple myeloma, red blood cell count(RBC) increase disease, hemolytic anemia and cancer etc. may result in the propagation of cell and accelerate, and makes nucleic acid conversion increase, causes uric acid to produce and increase.Malignant tumor causes cell considerable damage, nucleic acid conversion also to increase after the chemicotherapy of tumor, causes uric acid to produce and increases.Kidney disease includes that the detection of glomeruli filtration function caused in chronic glomerulonephritis, pyelonephritis, polycystic kidney, lead poisoning and hypertension late period etc. goes down, and can make underexcretion, cause serum Uric Acid Concentration to raise.Medicine such as thiazide diuretic, furosemide, ethambutol, pyrazinamide, low-dosage aspirin and nicotinic acid etc., contestable suppresses tubular excretion uric acid to cause hyperuricemia.It addition, renal transplant recipients long-term taking immunosuppressant also can occur hyperuricemia, may be relevant with immunosuppressant suppression tubular excretion uric acid.
Clinical manifestation
Gout is more common in middle-aged male, and women only accounts for 5%, and mainly postmenopausal women, gout has rejuvenation trend.The natural history of gout can be divided into the fourth phase, the most asymptomatic hyperuricemia phase, acute stage, intermission, chronic phase.Clinical manifestation is as follows:
1. acute gouty arthritis
Without obvious sign or the most tired, general malaise and joint sting etc. before most of patients outbreak.Typical onset is often waken up with a start because of arthralgia the late into the night, and pain Progressive symmetric erythrokeratodermia aggravates, and reaches peak at about 12 hours, and in tear sample, lancinate sample or sting and bite sample, it is difficult to stands.Affected joints and surrounding tissue is red, swollen, hot, pain and function limitation.More than spontaneous remission in a couple of days or 2 weeks.First-episode many infringements simple joint, part is above to be occurred in Metatarsophalangeal joint, the course of disease afterwards, and some patients involves this position.Secondly being the joints such as instep, heel, ankle, knee joint, wrist and elbow, getting involved less in the joint such as shoulder, hip, spinal column and temporo jaw, can involve multiple joint simultaneously, show as polyarthritis.Some patients can have heating, shiver with cold, have a headache, cardiopalmus and the General Symptoms such as feel sick, numeration of leukocyte can be accompanied to raise, erythrocyte sedimentation rate speeds and increases with c reactive protein.
2. interval stage of attack
Gout outbreak last from days is to can spontaneous remission after several weeks, general without obvious sequela shape, or leave over localised skin pigmentation, desquamation and scratchy etc., enter the asymptomatic intermission later, recurring after lasting several months, several years or more than ten years, most of patients recurred in 1 year, all the more more frequency, affected joints gets more and more, and duration of symptoms is more and more longer.Affected joints typically from lower limb to upper limb, develop to big joint from far-end Minor articulus, occur referring to, the joint involvement such as wrist and elbow, small number of patients can have influence on shoulder, hip, sacrum ilium, breast lock or joint of vertebral column, it is possible to involving the positions such as periarticular synovial bursa, tendon and stndon sheath, symptom tends to not being true to type.The small number of patients Non-intermittent phase, show in chronic arthritis after first attack.
3. the chronic gout stone pathological changes phase
Subcutaneous tophus and chronic gout stone arthritis are long-term significantly hyperuricemias, and a large amount of monosodium urate salt crystal deposition are in the result of subcutaneous, synovium of joint, cartilage, sclerotin and periarticular soft tissues.The typical parts that subcutaneous tophus occurs is auricle, is also common in the position such as periarticular and olecranon, heel string and patella synovial bursa of recurrent exerbation.Outward appearance is the yellow-white vegetation not of uniform size of subcutaneous protuberance, and skin surface is belittled, and discharges white powder or pastel after ulceration, prolonged does not heals.Subcutaneous tophus often with chronic gout stone arthritis depositing.The tophus that intraarticular deposits in a large number can cause joint bone destruction, periarticular tissue fibering and secondary degenerative change etc..Clinical manifestation is for continuing arthralgia, tenderness, deformity and dysfunction.Chronic phase symptom relaxes relatively, but also can have acute attack.
4. nephropathy
Chronic urate nephropathy urate crystals is deposited on renal interstitial, causes chronic renal tubule one interstitial nephritis.Clinical manifestation is that urine concentrating power declines, occur nocturia increase, low-gravity urine, small molecular protein urine, leukocyturia, slight hematuria and cylinderuria etc..Detection of glomeruli filtration function can be caused late period decline, renal insufficiency occurs.
Uric acid lithangiuria urine uric acid concentration increases in hypersaturated state, deposits in urinary system and forms calculus.Incidence rate in patient with gout is more than 20%, thereby increases and it is possible to before coming across gouty arthritis generation.Calculus smaller is gritty with urine ejection, can be asymptomatic；The greater can block urinary tract, causes renal colic, hematuria, dysuria, urinary system infection, pyelectasis and hydrops etc..
Acute urate nephropathy blood and the hurried rising of urine uric acid level, a large amount of uric acid crystals are deposited on renal tubules, collecting tubule etc., cause acute urinary tract obstruction.Clinical manifestation is oliguria, anuria, acute renal failure；Visible a large amount of uric acid crystal in urine.How to be caused by secondary reasons such as malignant tumor and chemicotherapies (i.e. tumor lysis syndrome) thereof.
Drug therapy
1. suppression uricopoiesis medicine is xanthine oxidase inhibitor.It is widely used in constitutional and secondary hyperuricemia, especially uric acid and produces the many types of person that maybe should not use uricosureic agent.
2. uricosureic agent is mainly by the suppression renal tubules heavily absorption to uric acid, reduces blood uric acid.It is mainly used in normal renal function, underexcretion type.For twenty-four-hour urine urate excretion > 3.57mmol or existing uric acid calculus person or the patient of chronic urate nephropathy, acute urate nephropathy patient, should not use.During medication, particularly start medication planted agent's several weeks alkalized urine and keep urine volume.Probenecid, sulphinpyrazone, benzbromarone.
The more external novel uric acid resisting medicines of the most novel uric acid resisting medicine have been used for clinic or carry out the clinical observation in later stage.
4. there are free uric acid and 2 kinds of forms of urate in the uric acid in alkalescent medicine urine, and as weak organic acid, uric acid can be converted into the higher urate of dissolubility, beneficially renal excretion in alkaline environment, reduces uric acid and deposits the kidney damage caused.The urine pH value of patient with gout is often below Healthy People, therefore answers alkalized urine while uric acid resisting is treated, and particularly during starting to take uricosureic agent, answers periodic monitoring to urinate pH value, is allowed to be maintained at about 6.5.Keep urine volume simultaneously, be prevention and the requisite measure for the treatment of gout related renal pathological changes.
5. treatment by Chinese herbs is started with marrow, whole body therapeutic, makes disease start to take a turn for the better, and human body recovers normal physiological function.
Medical material involved in the present invention all seen from be recorded in " China book on Chinese herbal medicine ".
Summary of the invention
It is desirable to provide a kind of medicine for treating gout, by selecting suitable medical material and proportioning thereof, reach safely and effectively to cure the purpose of gout.
In order to achieve the above object, the present invention is by the following technical solutions:
A kind of medicine for treating gout, it is characterized in that, it is to be prepared from by the raw medicinal material of following weight proportion: Pseudobulbus Cremastrae Seu Pleiones 4 parts, Semen Abutili 10 parts, Cortex schizophragmatis integrifolii radicis 12 parts, Radix Lantanae Camaraev 22 parts, Radix campsis 7 parts, Radix Thalictri Trichopi 30 parts, Resina Ferulae 1 part, Bi 12 parts, Fructus Ligustri Lucidi 10 parts.
Illustrate the method have the benefit that below in conjunction with theories of Chinese materia medica
It has been recognised by the inventors that the cause of disease of gout is due to surfeit delicious food, indulging in excessive drinking, overwork, the nervous or heresy such as damp and hot that is affected by the cold, cause coagulation of QI-blood, blockage of phlegm and blood stasis, joint is fallen ill through flow of QI being obstructed.Pathological change is the heresy of wind heat, and with wetting phase also, combined pathogens is for suffering from；Or innate excess of YANG in the body liver-yang hyperactivity, or food and drink is disloyal, accumulates raw expectorant heat, all can cause rheumatism pathogenic heat, or wind folder expectorant heat, retention in the meridians and collaterals joint, numbness choke blood, and be beriberoid pyretic arthralgia.Wind and cold folder is wet, attacks into meridians, solidifying puckery QI and blood, through flow of QI being obstructed, and sends out as anemofrigid-damp arthralgia.Arthromyodynia does not heals, QI-blood circulation smooth day very, then phlegm-turbidity and blood stasis blood chronic tying-in network, and cause the diseases such as joint sting, tuberosity, deformity.Evil love wound just, deficiency of spleen-YANG and kidneyYANG, cause astringency inducing eventually and have no right, precise and tiny under let out, weakness of the body.Therefore expelling wind and clearing away heat, removing dampness blood stasis dispelling, dispelling cold by warming the meridian, dissipating phlegm and removing blood stasis are then taked in treatment.
The present invention uses: Pseudobulbus Cremastrae Seu Pleiones heat-clearing and toxic substances removing, dispersing swelling and dissipating binds；Semen Abutili relieving stranguria by diuresis, laxation relieving constipation, stimulating milk secretion；Cortex schizophragmatis integrifolii radicis relaxing muscles and tendons and activating QI and blood in the collateral, expelling wind and activating blood circulation；Radix Lantanae Camaraev clearing away heat-fire, detoxicating and resolving stagnation of pathogens；Radix campsis cooling blood, expelling wind, promoting blood circulation to remove obstruction in the collateral；Radix Thalictri Trichopi expelling wind and removing dampness, reducing swelling and alleviating pain, detoxify parasite killing；Resina Ferulae disease removing food stagnancy, parasite killing preventing the attack (or recurrence) of malaria；Bi wind-damp dispelling, dampness removing is turbid；Fructus Ligustri Lucidi liver and kidney tonifying, clearind deficient heat, improving eyesight.All medicines share, and reach dispel the wind removing dampness, eliminating stagnation of stimulating the menstrual flow, warming and recuperating the spleen and kidney, effect of removing heat from blood dredging collateral.
Below in conjunction with clinical laboratory data beneficial effects of the present invention is described:
1, physical data
Inventor collects 94 example patient with gout between in July ,-2015 in March, 2012 altogether.It is randomly divided into: treatment group 47 example, matched group 47 example.Male 42 examples of wherein treatment group, female 5 example, age 33～61 years old, the course of disease 2 months～3 years；Matched group man 44 examples, female 3 example, between age 35～65 years old, the course of disease 1 month～5 years.The data such as two groups of sexes, age, courses of disease there was no significant difference, and has comparability.
Diagnostic criteria
1. the joint of recurrent exerbation is red, swollen, hot, bitterly, and typical parts is foot metatarsophalangeal joints, and other includes ankle, knee joint, wrist, elbow, metacarpophalangeal joints etc..Course of disease elder can have joint deformity, arthroedema, periarticular or auricle portion tophus to be formed, and can overflow white urate crystal, also can detect urate crystal in hydrarthrosis after calculus ulceration.The General Symptomies such as fear of cold heating, headache, whole body discomfort it are often accompanied by during outbreak.
2. in being more common in, elderly men, overweight or overweight people is in the majority.
3. blood uric acid is generally higher than 380 μm ol/L(6.4mg/dl).
4. urine uric acid discharge capacity increases, and is easily formed urate calculus and gouty nephropathy, and the long person of the course of disease causes renal hypofunction.
5. pathological changes joint x-ray takes the photograph the punched-out defect district that sheet visible joint face is rounded or irregular, and locally sclerotin can have osteoporosis to change.Pyelography or B-type ultrasonography prompting renal calculus exist.
6. the arthritis of other reasons is got rid of.
1. inclusive criteria meets diagnostic criteria；2. the age 18～70 years old；3. compliance is good；Sign Informed Consent Form the most voluntarily.
Exclusion standard 1. gestation, women breast-feeding their children；2. suffer from severe cardiac, lung, liver, renal disease patient；3. spiritedness systemic disease, it is impossible to partner treatment person；4. through the patient of other drug treatment after morbidity.
2, Therapeutic Method
Treatment group is administered orally the capsule that the present invention prepares according to specific embodiment 3, three times a day.Treat 2 months.
Matched group is administered orally probenecid sheet, each 0.25g, three times a day.Treat 2 months.
3, criterion of therapeutical effect and therapeutic outcome
3.1 criterion of therapeutical effect
1. recovery from illness: in clinical symptom disappearance, blood and urine, uric acid content is normal, normal renal function；
The most effective: remission, in blood and urine, uric acid content is close to normal, and renal function takes a turn for the better；
The most invalid: the person of being not improved such as symptom, uric acid after treatment.
3.2 treatment statistical results are shown in Table 1.
1 liang of table group comparitive study
| Group | n | Recovery from illness | Effectively | Invalid | Total effective rate (%) | Obvious adverse reaction example |
| Treatment group | 47 | 19 | 25 | 3 | 94% | 0 |
| Matched group | 47 | 13 | 20 | 14 | 70% | 0 |
Visible, gout can safely and effectively be treated by the medicine that the present invention prepares, and cure rate is high.
Detailed description of the invention
In order to be more fully understood that and implement the present invention, further illustrate the present invention below in conjunction with specific embodiment.
Embodiment 1
Weigh: Pseudobulbus Cremastrae Seu Pleiones 4 grams, Semen Abutili 10 grams, Cortex schizophragmatis integrifolii radicis 12 grams, Radix Lantanae Camaraev 22 grams, Radix campsis 7 grams, Radix Thalictri Trichopi 30 grams, Resina Ferulae 1 gram, Bi 12 grams, Fructus Ligustri Lucidi 10 grams；Add 8 times amount water, decoct 1.5 hours, filter；Filtering residue adds 6 times amount water, decocts 1 hour, filters；Merging filtrate, is concentrated into 120 grams, must meet the decoct of one day consumption of adult normal.
For treating gout.Oral, the most once.
Embodiment 2
Weigh: Pseudobulbus Cremastrae Seu Pleiones 4 grams, Semen Abutili 10 grams, Cortex schizophragmatis integrifolii radicis 12 grams, Radix Lantanae Camaraev 22 grams, Radix campsis 7 grams, Radix Thalictri Trichopi 30 grams, Resina Ferulae 1 gram, Bi 12 grams, Fructus Ligustri Lucidi 10 grams；Add 10 times amount water, decoct 2 hours, filter；Filtering residue adds 8 times amount water, decocts 1.5 hours, filters；Merging filtrate, concentrates, and is dried, and packaging must meet the powder of one day consumption of adult normal.
For treating gout.Oral, every bu is taken for twice sooner or later.
Embodiment 3
Weigh: Pseudobulbus Cremastrae Seu Pleiones 4 grams, Semen Abutili 10 grams, Cortex schizophragmatis integrifolii radicis 12 grams, Radix Lantanae Camaraev 22 grams, Radix campsis 7 grams, Radix Thalictri Trichopi 30 grams, Resina Ferulae 1 gram, Bi 12 grams, Fructus Ligustri Lucidi 10 grams；Add 6 times amount water, decoct 3 times, decoct 1 hour every time, merge decoction liquor, concentrate, be dried, load capsule shells, the capsule of one day consumption of adult normal must be met.
For treating gout.Oral, every bu morning, noon and afternoon take for three times.
Claims (4)
1. the medicine being used for treating gout, it is characterized in that, it is to be prepared from by the raw medicinal material of following weight proportion: Pseudobulbus Cremastrae Seu Pleiones 4 parts, Semen Abutili 10 parts, Cortex schizophragmatis integrifolii radicis 12 parts, Radix Lantanae Camaraev 22 parts, Radix campsis 7 parts, Radix Thalictri Trichopi 30 parts, Resina Ferulae 1 part, Bi 12 parts, Fructus Ligustri Lucidi 10 parts.
2. the medicine for treating gout as claimed in claim 1, it is characterized in that, its preparation method is: weigh: Pseudobulbus Cremastrae Seu Pleiones 4 parts, Semen Abutili 10 parts, Cortex schizophragmatis integrifolii radicis 12 parts, Radix Lantanae Camaraev 22 parts, Radix campsis 7 parts, Radix Thalictri Trichopi 30 parts, Resina Ferulae 1 part, Bi 12 parts, Fructus Ligustri Lucidi 10 parts；Add 8 times amount water, decoct 1.5 hours, filter；Filtering residue adds 6 times amount water, decocts 1 hour, filters；Merging filtrate, is concentrated into 120 parts, obtains decoct；Above-mentioned part each means weight portion.
3. the medicine for treating gout as claimed in claim 1, it is characterized in that, its preparation method is: weigh: Pseudobulbus Cremastrae Seu Pleiones 4 parts, Semen Abutili 10 parts, Cortex schizophragmatis integrifolii radicis 12 parts, Radix Lantanae Camaraev 22 parts, Radix campsis 7 parts, Radix Thalictri Trichopi 30 parts, Resina Ferulae 1 part, Bi 12 parts, Fructus Ligustri Lucidi 10 parts；Add 10 times amount water, decoct 2 hours, filter；Filtering residue adds 8 times amount water, decocts 1.5 hours, filters；Merging filtrate, concentrates, and is dried, and packaging obtains powder；Above-mentioned part each means weight portion.
4. the medicine for treating gout as claimed in claim 1, it is characterized in that, its preparation method is: weigh: Pseudobulbus Cremastrae Seu Pleiones 4 parts, Semen Abutili 10 parts, Cortex schizophragmatis integrifolii radicis 12 parts, Radix Lantanae Camaraev 22 parts, Radix campsis 7 parts, Radix Thalictri Trichopi 30 parts, Resina Ferulae 1 part, Bi 12 parts, Fructus Ligustri Lucidi 10 parts；Add 6 times amount water, decoct 3 times, decoct 1 hour every time, merge decoction liquor, concentrate, be dried, load capsule shells, obtain capsule；Above-mentioned part each means weight portion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610287701.7A CN105833025A (en) | 2016-05-04 | 2016-05-04 | Drug for treating gout |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610287701.7A CN105833025A (en) | 2016-05-04 | 2016-05-04 | Drug for treating gout |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105833025A true CN105833025A (en) | 2016-08-10 |
Family
ID=56590521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610287701.7A Pending CN105833025A (en) | 2016-05-04 | 2016-05-04 | Drug for treating gout |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105833025A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1249192A (en) * | 1998-09-30 | 2000-04-05 | 鄢聚金 | Chinese medicine for treating gout |
| CN102727753A (en) * | 2012-06-19 | 2012-10-17 | 卞毓平 | Traditional Chinese medicine composition used for treating gout, and preparation method and application thereof |
| CN103386033A (en) * | 2013-06-27 | 2013-11-13 | 张兴保 | Deer blood wine for treating rheumatism and gout and preparation method thereof |
| CN104274642A (en) * | 2014-11-10 | 2015-01-14 | 胡健 | Traditional Chinese medicine for treating gout |
-
2016
- 2016-05-04 CN CN201610287701.7A patent/CN105833025A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1249192A (en) * | 1998-09-30 | 2000-04-05 | 鄢聚金 | Chinese medicine for treating gout |
| CN102727753A (en) * | 2012-06-19 | 2012-10-17 | 卞毓平 | Traditional Chinese medicine composition used for treating gout, and preparation method and application thereof |
| CN103386033A (en) * | 2013-06-27 | 2013-11-13 | 张兴保 | Deer blood wine for treating rheumatism and gout and preparation method thereof |
| CN104274642A (en) * | 2014-11-10 | 2015-01-14 | 胡健 | Traditional Chinese medicine for treating gout |
Non-Patent Citations (1)
| Title |
|---|
| 高菁等: "商宪敏教授治疗痛风的临床经验", 《现代中医临床》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104825938A (en) | Traditional Chinese medicine composition for treating gout | |
| CN107468768B (en) | Qiang medicine composition and application thereof | |
| CN104815318A (en) | Traditional Chinese medicine preparation for treating gout | |
| CN105287748B (en) | The Chinese materia medica preparation and preparation method thereof for treating hyperuricemia | |
| CN105641564A (en) | Medicine for treating gouty arthritis by combining oral administration and external application of traditional Chinese medicines | |
| CN110354222A (en) | It is a kind of for treating the external drug of gout | |
| CN109820943A (en) | A kind of strong medicine preparation and preparation method thereof for treating gout | |
| CN102430015A (en) | Traditional Chinese medicinal preparation for treating nephritis and uremia as well as preparation method thereof | |
| CN108837106A (en) | A kind of drug that treating goat and preparation method | |
| CN103908603B (en) | A kind of Chinese medicine composition treating gout and preparation method thereof | |
| CN1248727C (en) | Insensitive impediment capsule and its manufacturing method | |
| CN105267321A (en) | Medicine for treating gouty arthritis | |
| CN105833025A (en) | Drug for treating gout | |
| CN106620435B (en) | Traditional Chinese medicine composition for treating gouty arthritis and application thereof | |
| CN110478416A (en) | The composition and its preparation method and application for treating rheumatic rheumatoid arthritis | |
| CN103520638B (en) | A kind of Traditional Chinese medicine compound composition for the treatment of prostate hyperplasia and preparation method thereof and application thereof | |
| CN105853734A (en) | Drug for treating rheumatoid arthritis | |
| CN110893206B (en) | Externally applied medicine for treating rheumatic arthritis and preparation method thereof | |
| CN105617161A (en) | Traditional Chinese medicine composition for treating gout | |
| CN105561038A (en) | Traditional Chinese medicine composition for treating gout | |
| CN104491799B (en) | A kind of traditional Chinese powder medicine for application treatment rheumatoid arthritis | |
| CN114588241A (en) | Traditional Chinese medicine composition for treating gout and hyperuricemia | |
| CN104547086A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis | |
| CN118320028A (en) | Traditional Chinese medicine composition, preparation method and application | |
| CN104435339A (en) | Kidney-tonifying and calculus-removing compound preparation for urinary system and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160810 |
|
| WD01 | Invention patent application deemed withdrawn after publication |